AKTS News
Archived Headlines
- Aktis Oncology increases proposed IPO deal size by 50% to $300 million, adding a $100 million commitment from partner Eli Lilly 01/07/26
- Phase 1 solid tumor biotech Aktis Oncology sets terms for $200 million IPO; expected to trade on Friday 1/9 in first sizable IPO of 2026 01/05/26
- US IPO Week Ahead: Aktis Oncology set to open 2026 IPO Market 01/02/26
- US IPO Weekly Recap: Medline and Andersen soar ahead of Christmas holiday 12/19/25
- Phase 1 solid tumor biotech Aktis Oncology files for a $100 million IPO 12/19/25
Renaissance Capital's January IPO Market Update
The 2026 IPO market started the year on reasonably steady footing as nine listings raised a combined $2.6 billion in January. Despite a mounting backlog of startups indicating IPO plans this year, many initially stayed on the sidelines and let others test...read more
US IPO Weekly Recap: Aktis Oncology leads as first sizable 2026 IPO
Three IPOs and five SPACs priced this week. Six IPOs and two SPACs submitted initial filings. In the first sizable deal of 2026, solid tumor biotech Aktis Oncology (AKTS) priced its upsized IPO at the high end of the range to raise $318 million at a $1.0...read more
Biotech IPOs are back: Why 2026 could mark a hot year for the sector
After a period of uneven performance, the biotech IPO market is beginning to show signs of renewed momentum. On Monday, radiopharmaceutical oncology biotech Aktis Oncology (AKTS) launched a $200 million IPO; two days later, the company upsized the deal by 50%...read more
Phase 1 solid tumor biotech Aktis Oncology prices IPO at $18, the high end of the range
Aktis Oncology, a Phase 1 biotech developing targeted radiopharmaceuticals to treat solid tumors, raised $318 million by offering 17.7 million shares at $18, the high end of the range of $16 to $18. The company originally planned to offer 11.8 million shares at ...read more